At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 42 enrolled
Drug / intervention
Ticagrelor +2 moredrug
Likely dose
Ticagrelor 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study
In Brief
A Phase 4 clinical trial evaluating Ticagrelor, Clopidogrel, and 1 other intervention for Coronary Artery Disease and Diabetes Mellitus. Completed, enrolled 42 participants.
Detailed Summary
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
Primary CompletionJun 2015
First PostedApr 2016
TodayJul 2026
First PostedApr 19, 2016
Enrollment StartMar 1, 2014
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.2 years ago
Interventions
Ticagrelordrug
Ticagrelor 90 mg twice daily
Clopidogreldrug
Clopidogrel 150 mg once daily
Standard medical therapydrug
Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions